SA
RPRX logo
Royalty Pharma plc(RPRX)
Updated 12:40 PM ETAbout this dataData status
$68.01▼-0.66 (-0.96%)

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 26.1 · elevated volatility

Overview →

Royalty Pharma plc (RPRX)

R&D to Revenue

19.01%

Fiscal year · Period ending:

RPRX logo

RPRX R&D to Revenue

Latest reported19.01%
RPRX FY R&D/Revenue (5.95% → 19.01%)
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

RPRX r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Royalty Pharma plc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
19.006%
0.0884%
2.2085%
7.9164%
8.7393%
1.2387%
4.5769%
21.8737%
7.3762%
4.8482%
5.9538%

Frequently asked questions: RPRX r&d to revenue

What is Royalty Pharma plc (RPRX)'s current r&d to revenue?

Royalty Pharma plc (RPRX)'s latest reported r&d to revenue (Fiscal year) is 19.01% as of Dec 31, 2025. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for RPRX?

Stock Alarm Pro provides 11 dated annual fiscal periods observations for Royalty Pharma plc (RPRX)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare RPRX's r&d to revenue to peers or set an alert?

You can open RPRX's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on RPRX delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.